CardioGenics Holdings Inc

CardioGenics Holdings Inc

CGNH
CardioGenics Holdings IncUS flagOther OTC
0.00
USD
- -
- -
12,000.00Market Cap
CardioGenics Holdings Inc
CGNH
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
TTM
FRC
0.73
0.56
0.23
0.1
0.06
0.05
0.04
0.04
0.03
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-11.72
-9.33
-1.51
-0.68
-0.47
-0.42
-0.85
-2.53
-0.5
-0.95
-0.04
-0.11
-0.02
-0.05
-0.04
-0.02
-0.01
Basic EPS, GAAP
-6.72
-3.27
-0.44
-0.6
-0.41
-0.35
-0.52
-0.1
-0.23
-0.02
-0.04
-0.03
-0.02
-0.01
-0.01
-0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-12.57
-19.35
-14.47
-10.91
-10.1
-10.12
-11.35
-13.01
-11.11
-1.09
-0.71
-0.75
-0.76
-0.79
-0.77
-0.52
-0.49
Book Value per Share
0.97
0.09
-0.47
-0.02
0.09
-0.3
-1.05
-3.15
0.02
0.06
0.03
0.01
-0.01
-0.02
-0.02
-0.02
-0.02
Tangible Book Value per Share
1
2
3
4
4
4
4
5
6
30
50
54
56
57
62
94
101
Basic Weighted Avg Shares
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-1,975.66
-1,482.69
-643.1
-658.21
-783.59
-710.04
-1,408.18
-846.53
-1,002.15
- -
- -
-63,040.75
-99,368.08
- -
- -
- -
- -
Operating Margin (%)
- -
10
1
1
- -
- -
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-17
-17
-4
-3
-2
-2
-4
-12
-3
-29
-2
-6
-1
-3
-3
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,599.15
-1,664.09
-643.67
-668.27
-791.94
-788.3
-2,181.78
-5,792.41
-1,599.39
- -
- -
-64,495.45
-100,851.89
- -
- -
- -
- -
Profit Margin (%)
1
- -
-1
- -
- -
1
-3
-12
- -
2
2
- -
-1
-1
-1
-2
-2
Working Capital
- -
- -
- -
- -
- -
2
2
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
2
- -
-1
- -
- -
-1
-4
-15
- -
2
2
1
-1
-1
-1
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.72
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Jul'15
Oct'15
Jan'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
76
92
93
Market Capitalization
3
4
3

Working Capital

FRC

in mil. unless spec.
Jul'15
Oct'15
Jan'16
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
205.94%
-24.64%
35.32%
Free Cash Flow
19.07%
-21.69%
1.94%
Net Income, GAAP
125.35%
38.42%
-28.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.01
-0.01
-0.01
- -
-0.04
2015
-0.01
- -
-0.01
- -
-0.02
2016
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
Business
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products targeting the immunoassay segment of the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally; its core offerings include the QL Care Analyzer, a portable, stand-alone, automated point-of-care immunoassay analyzer utilizing proprietary self-metering cartridges for on-site testing; a series of immunoassay tests designed to identify cardiac markers in blood during heart attacks; and paramagnetic beads serving as solid surfaces for heterogeneous immunoassay tests employed by clinical and research laboratories. Founded in 1997 and headquartered at 6295 Northam Drive, Unit 8, Mississauga, Ontario, L4V 1W8, Canada, the company, led by Founder, CEO and Director Dr. Yahia Gawad, focuses on innovative, cost-effective, patent-protected technologies to enhance healthcare professionals' diagnostic capabilities and patient management while reducing costs. Originally known as Jag Media Holdings Inc., it changed its name to CardioGenics Holdings Inc. in 2009; among its earlier strategic moves, it entered an asset purchase agreement in November 2015 to acquire substantially all assets of Ontario-based Plasticap, including manufacturing expertise for plastics to support production of its QL Care Analyzer cartridges and expansion into healthcare plastics, while maintaining Plasticap's client base, with related real property transactions finalized separately.

Company News

APIChat
  • CardioGenics (OTCMKTS:CGNH) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

  • CardioGenics (OTCMKTS:CGNH) & Avanos Medical (NYSE:AVNS) Financial Review

  • CardioGenics (OTCMKTS:CGNH) Share Price Passes Above 200-Day Moving Average – Here’s Why

  • Comparing CardioGenics (OTCMKTS:CGNH) & LENSAR (NASDAQ:LNSR)

  • Contrasting DarioHealth (NASDAQ:DRIO) and CardioGenics (OTCMKTS:CGNH)

  • Head-To-Head Analysis: IDEXX Laboratories (NASDAQ:IDXX) vs. CardioGenics (OTCMKTS:CGNH)

  • Head-To-Head Contrast: CardioGenics (OTCMKTS:CGNH) versus Nielsen (OTCMKTS:NLSN)